Ecleralimab
Based on 1 Customer Validation
Ecleralimab (CSJ-117; NVP-CSJ117) is a Fab-IgG1-λ2 antibody targeting the thymic stromal lymphopoietin (TSLP). Ecleralimab significantly attenuates allergen-induced airway responses and inflammation. Ecleralimab can be used for the study of inhaled asthma.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 97.35%
- CAS. Nr.: 2415207-91-7
- Molecular Weight:46.62 kDa
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
TSLP
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized TSLP Protein, Human can bind Ecleralimab. The EC50 for this effect is 17.78 ng/mL.
Product Details
-
CAS. Nr. 2415207-91-7
-
Accession Q969D9-1
-
Synonyms CSJ-117; NVP-CSJ117
-
Molecular Weight 46.62 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Fab-G1-lambda2
-
Format
-
Fab-G1-lambda2
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Reinheit
97.35%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Versand
Shipping with dry ice.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)